ArticleNature biomedical engineering2025
Focused ultrasound-microbubble treatment arrests the growth and formation of cerebral cavernous malformations.
Article in Nature biomedical engineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Acoustically driven micro/nanobubbles: from fundamental mechanisms to biomedical applications.Microsystems & nanoengineering · 2026Review
- Inhibition of MEKK3 Prevents Cerebral Cavernous Malformation Progression Via Restoring Endothelial Integrity and Restricting Microglial Activation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Blood-Brain Barrier Regulation: Evolving From Classic Strategies to Electrochemical Ion and Reactive Oxygen Species Control.Advanced healthcare materials · 2026Review
- Narrowing of glioma vascular caliber via chronic VEGFR2 blockade improves the uniformity of focused ultrasound-mediated small molecule drug delivery.Journal of controlled release : official journal of the Controlled Release Society · 2026Article
- Tea-derived natural nanodrug simultaneously enables real-time fluorescent tracking and noninvasive treatment of neuroinflammation in Alzheimer's disease.Journal of nanobiotechnology · 2026Article
- The effect of Vitamin D and Vitamin D-based therapies on hemorrhage risk in cerebral cavernous malformations: A systematic review.Surgical neurology international · 2026Review
- Precise Manipulation of Bubble Cavitation and Blood-Brain Barrier Modulation using Temporal Interference Ultrasound.BME frontiers · 2026Article
- The effect of statins on the risk of bleeding in cerebral cavernous malformations: A systematic review and meta-analysis.Surgical neurology international · 2026Review
- ASMase Activation in Ultrasound-Stimulated Radiation Enhancement Using MRI-Guided Focused Ultrasound.Cells · 2025Article
- Focused ultrasound-microbubble treatment arrests the growth and formation of cerebral cavernous malformations.Nature biomedical engineering · 2025Article
- Focused ultrasound augments the delivery and penetration of model therapeutics into cerebral cavernous malformations.Journal of controlled release : official journal of the Controlled Release Society · 2025Article
- Ultrasound-targeted microbubble destruction: a prospective strategy for treating cardiovascular disease.Frontiers in cardiovascular medicine · 2025Review
Corrections and comments
- Update of
Authors and funding
17 authors.
Funding
Abstract
Cerebral cavernous malformations (CCMs) are vascular lesions within the central nervous system that cause debilitating neurological symptoms. Currently, surgical excision and stereotactic radiosurgery, the primary treatment options, pose risks to some patients. Here we tested whether pulsed, low intensity, focused ultrasound-microbubble (FUS-MB) treatments control CCM growth and formation in a clinically representative Krit1 null murine model. FUS-MB under magnetic resonance imaging (MRI) guidance opened the blood-brain barrier, with gadolinium contrast agent deposition most evident at perilesional boundaries. Longitudinal MRI revealed that, at 1 month after treatment, FUS-MB halted the growth of 94% of treated CCMs. In contrast, untreated CCMs grew ~7-fold in volume. FUS-MB-treated CCMs exhibited a marked reduction in Krit1 null endothelial cells. In mice receiving multiple FUS-MB treatments with fixed peak-negative pressures, de novo CCM formation was reduced by 81%, indicating a prophylactic effect. Our findings support FUS-MB as a minimally invasive treatment modality that can safely arrest murine CCM growth and prevent de novo CCM formation in mice. If proven safe and effective in clinical trials, FUS-MB treatment may enhance therapeutic options for CCM patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.